Test the pathway
Compare ECP-guided personalization with questionnaire/basic-laboratory personalization using comparable active-catalogue access, practitioner contact and adherence support.
ECP · Master Evidence Cohort & Protocol
From individual signals.
To independent evidence.
A physician-supervised research program to test whether explainable, genotype-responsive personalization delivers measurable molecular value.
4Distinct cohorts
6Evidence modules
180Day follow-up · randomized stage
Proposed study design for sponsor, investor and partner discussion. No study results or demonstrated efficacy are represented.
Source basis · R2 §§3–4, 11
01 · Scientific objective
A question worth testing.
Does the ECP-guided pathway improve an independent molecular outcome beyond credible conventional personalization?
Anchor the biology
Evaluate modeled outputs against independent laboratory measurements rather than treating a changing platform score as proof of benefit.
Understand the individual
Examine prospectively defined molecular strata, repeated within-person dynamics and longer-term response.
Source basis · R2 §§3, 9, 11
02 · Study architecture
One protocol. Four distinct populations.
Nested scientific cohorts deepen the initial population; a separate randomized stage tests decision utility.
Cohort A · 75 unique adults
Core operational population · 90 days · first 25 form the sentinel subset
B · Deep phenotyping
30–40 participants · 40 planning scenario
14–28 intensive days + Day 90
C · Molecular enrichment
36–60 participants · 60 planning scenario
Genotype / epigenotype-informed analysis
B and C may overlap. Neither is added to the 75-person core count.
D · Independent randomized decision-utility stage
New participants · three arms · Day 90 assessment and committed Day 180 follow-up
Separately consented epigenomic substudy: up to 100 across the program; not an additional cohort or additive enrollment.
Source basis · R2 §4
03 · Enrollment scenario explorer
Scale the conversation. Not the claims.
Switch between operational and statistical-planning scenarios to inspect non-additive program counts.
180Cohort D randomized
60Participants per arm · equal allocation
255Unique program participants · 75 + D
Planning scenarios, not an approved sample-size requirement or a completed power determination. Nested groups and the epigenomic substudy are never added to total enrollment.
Source basis · R2 §§4.1–4.2, 13
04 · Target participants
Adults able to participate in a rigorous journey.
A physician-led wellness setting with prospective molecular-strata recruitment and modular participant permissions.
Core population
Adults age 18 or older who can complete assigned visits, wear standardized study devices and provide scheduled specimens.
Prospective enrichment
MTHFR rs1801133 TT and COMT rs4680 Met/Met strata with prospectively recruited matched comparators.
Participant protections
Medical suitability assessment; activity-specific permissions; separate optional epigenomic consent; documented safety and exposure review.
The design includes activity-specific exclusions for device contraindications, unstable conditions and pregnancy in intensive/interventional activities. Acute illness prompts physician review and deferral of affected procedures.
Source basis · R2 §§5–6
05 · Participant workflow
A continuous journey. A traceable record.
Every measurement, specimen and practitioner decision contributes to a connected evidence record.
Screen & consent
Eligibility, safety, modular permissions and prospective enrichment.
Establish baseline
Standardized sensor acquisition, molecular sampling and context.
Observe & review
Repeated measurement, practitioner oversight and adherence records.
Compare & follow
Independent outcomes, arm comparisons and longitudinal follow-up.
| Population / activity | Baseline | Day 7 | Day 14 | Day 90 | Day 180 |
|---|---|---|---|---|---|
| Core operational | Assessment / assigned panel | As assigned | As assigned | Follow-up | — |
| Deep phenotyping | Sensors + molecular | Molecular / intensive | Molecular / intensive | Molecular + follow-up | — |
| Epigenomic substudy | Paired specimen start | — | Exploratory intensive only | Paired specimen end | Supportive only |
| Randomized stage | Assessment → allocation | Follow-up support | Follow-up support | Outcome assessment | Committed outcome follow-up |
Source basis · R2 §§5.1, 7, 11
06 · Evidence explorer
Six complementary evidence modules.
Select a module to trace the question, measurement and population. These are distinct forms of evidence—not interchangeable claims.
Operational feasibility
Retention, completeness, consent and specimen provenance · Cohort A.
Source basis · R2 §3, Table 3-1; §§8–11, 13
07 · Molecular endpoint
The outcome is independent of the engine.
The Program Molecular Reference Index (PMRI) is the proposed independent research outcome; the Exceptional Point Index (EPI) is model-derived.
| Proposed PMRI component | Biological domain | Intended role |
|---|---|---|
| Urinary F2-isoprostane / creatinine | Oxidative damage | Essential reference component |
| Glutathione redox · GSSG/GSH | Antioxidant / redox balance | Essential reference component |
| High-sensitivity CRP | Inflammatory context | Context component |
| Homocysteine | One-carbon context | Context component |
Independent comparison—not circular validation.
Compare modeled trajectories with laboratory anchors. For randomized utility, compare PMRI change between assigned pathways.
The component structure is a proposed research specification. PMRI is not a validated clinical surrogate or diagnostic. EPI and modeled ROS/redox outputs are not direct intracellular ROS measurements.
Source basis · R2 §§3, 9
08 · Randomized design
A credible comparator makes the answer valuable.
Three pathways with matched practitioner contact and adherence support. The primary comparison is ECP-guided versus conventional personalization.
| Randomized arm | Personalization approach | Product / support design | Comparison role |
|---|---|---|---|
| Arm A · ECP-guided | Prospectively specified ECP routing; practitioner review | Active catalogue and serving opportunities comparable to B | Primary pathway of interest |
| Arm B · Conventional | Questionnaire + basic-laboratory rules; no genotype/sensor routing | Same active-catalogue opportunities as A; not placebo | Primary comparator |
| Arm C · Behavioral / neutral | Behavioral guidance; neutral formats where feasible | Matched practitioner contact and adherence support | Key secondary comparator |
Proposed equal allocation · independent laboratory outcomes · design-level masking of laboratory and analytical roles. The study compares whole pathways; it does not isolate the contribution of any single sensor, genotype term or ingredient.
Source basis · R2 §11
09 · Endpoint framework
Measure reliability, meaning and added value.
A connected endpoint map keeps operational, mechanistic and randomized questions scientifically distinct.
| Evidence domain | Endpoint family | Interpretive use |
|---|---|---|
| Operational | Retention, completeness, consent, provenance | Practical conduct at the tested scale |
| Analytical | ICC; concordance; Bland–Altman; quality retention; drift | Reliability and agreement, not molecular benefit |
| Molecular | Within-person EPI–PMRI association | Independent biological anchoring |
| Genomic / epigenomic | Prospective interactions; calibration; incremental performance | Molecular-strata information, not pilot subgroup efficacy |
| Longitudinal | Amplitude; time-to-peak; recovery; deviation area; molecular concordance | Individual perturbation / recovery behavior |
| Randomized utility | PMRI change: A vs B; A vs C; longer-term comparison | Added pathway value on an independent research outcome |
Outcome assessments span Day 90 and Day 180 in the randomized stage. No effect size or study benefit is presented as an observed result.
Source basis · R2 §9, Table 9-3; §§10–13
10 · Governance by design
Human oversight. Independent evaluation.
A role-based scientific and data-governance architecture is intended to protect participants and preserve interpretable evidence.
Scientific authority
CH LABS, LLC · sponsor
Dr. Boris Nikolov · Lead Scientific Investigator
Clinical oversight, protocol conduct and safety responsibilities organized by role.
Evidence integrity
Version-controlled model and analysis specifications; separation of development and validation evidence; independent statistical evaluation and traceable changes.
Data stewardship
Pseudonymized records; identity separation; least-privilege omics access; source-to-output provenance; audit and reproducibility records.
Practitioner review remains central: recommendations are reviewed, modified, held or rejected within the study’s safety and oversight framework.
Source basis · R2 §§1, 11, 14–15
11 · Expectations
What participation asks. What the program delivers.
A shared research effort with clear contributions and tangible evidence products.
| Contributor | Expected contribution | Intended evidence product |
|---|---|---|
| Participants | Assigned visits, specimens, standardized device use and context reporting | Consented longitudinal records and linked assessments |
| Clinical partners | Physician oversight, research coordination, specimen workflow and participant support | Documented conduct, safety and operational dataset |
| Laboratory / technology partners | Controlled assays, source records, instrument support and quality documentation | Independent molecular and analytical evidence |
| Scientific / data partners | Prospective analysis, reproducibility and governed evaluation | Version-specific analyses and publication-ready methods |
| Sponsors / investors | Financial or in-kind support aligned to a defined research scope | A structured evidence package to inform subsequent decisions |
Source basis · Study contributions synthesized from R2 §§7–15; engagement framing proposed for this presentation
12 · Implications
Useful evidence includes a negative answer.
The value of the design is its ability to distinguish added pathway value from product access, support and conventional personalization.
| Illustrative result pattern | Scientific interpretation |
|---|---|
| A better than B and C | Evidence consistent with added ECP-pathway value on the tested outcome. |
| A better than C; similar to B | No demonstrated incremental ECP-routing advantage over conventional personalization. |
| A and B better than C | Active personalized access may help; ECP routing is not shown superior. |
| All arms similar | No demonstrated benefit on the tested molecular endpoint. |
| B better than A | Evidence favors conventional personalization for the tested version and setting. |
Interpretations are conditional on the pre-specified analysis and evidence integrity. None establishes diagnosis, disease prevention, treatment efficacy or guaranteed commercial return.
Source basis · R2 §11, Table 11-3; §§3, 9
13 · Sponsor & partner invitation
Help build the evidence.
Support a scientifically disciplined test of individualized, practitioner-supervised precision wellness.
Sponsor a defined workstream
Back clinical operations, independent assays, analytical validation or governed data production.
Contribute capability
Bring clinical capacity, measurement infrastructure, laboratory expertise or independent scientific evaluation.
Align a research commitment
Define the contribution, evidence deliverable, reporting cadence and contractual scope.
Engagement options are proposed discussion paths, not executed partnerships, investment terms, promised results or pre-existing commitments.
Source basis · Engagement framing proposed for this presentation; scientific scope from R2 §§3–15
14 · Source & interpretation
Scientific clarity. A focused invitation.
Presentation content is derived from the Master Elevate Care Program Evidence Cohort Design.
Research presentation · not a results report
Enrollment figures are labeled planning scenarios. Scientific outputs remain research constructs. The presentation describes intended study architecture and does not represent enrollment authorization, product release, regulatory clearance or demonstrated benefit.